Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters

AIDS Research and Human Retroviruses

Volumn 15, Issue 15, 1999, Pages 1333-1338

  Lori, F ^a,e   Rosenberg, E ^b   Lieberman, J ^c   Foli, A ^a   Maserati, R ^a   Seminari, E ^a   Alberici, F ^d   Walker, B ^b   Lisziewicz, J ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c CENTER FOR BLOOD RESEARCH   (United States)

^d Divisione Malattie Infettive   (Italy)

^e RIGHT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; HYDROXYUREA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

EID: 0033544002     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922299310034     Document Type: Article

References (31)

1. Chun TW, Engel D, Berrey MM, Shea T, Corey L, and Fauci AS: Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998;95:8869-8873.
2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, and Siliciano RF: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
3. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, and Fauci AS: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-13197.
4. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, and Richman DD: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278: 1291-1295.
5. Gao WY, Cara A, Gallo RC, and Lori F: Low levels of deoxynucleotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90:8925-8928.
6. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J, and Gallo RC: Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994;266:801-805.
7. Malley SD, Grange JM, Hamedi-Sangsari F, and Vila JR: Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 1994;91:11017-11021.
8. Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, Nugier F, Grange J, Malley S, Hamedi-Sangsari F, and Vila J: Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:36-40.
9. Lori F, Malykh AG, Foli A, Maserati R, De AA, Minoli L, Padrini D, Degli AA, Barchi E, Jessen H, Wainberg MA, Gallo RC, and Lisziewicz J: Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses 1997;13:1403-1409.
10. Lisziewicz J, Jessen H, Finzi D, Siliciano RF, and Lori F: HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet 1998;352:199-200.
11. Donehower RC: An overview of the clinical experience with hydroxyurea. Semin Oncol 1992;19:11-19.
12. De Antoni A, Foli A, Lisziewicz J, and Lori F: Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy. J Infect Dis 1997;176:899-903.
13. Bagnarelli P, Valenza A, Menzo S, Manzin A, Scalise G, Varaldo PE, and Clementi M: Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo. J Virol 1994; 68:2495-2502.
14. Rutschmann OT, Opravil M, Iten A, Malinverni R, Vernazza PL, Bucher HC, Bernasconi E, Sudre P, Leduc D, Yerly S, Perrin LH, and Hirschel B: A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998;12:F71-F77.
15. De Boer RJ, Boucher CA, and Perelson AS: Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998;12:1567-1570.
16. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis JPA, Holohan MK, Leavitt R, Boone G, and Richman DD: Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998;339:1261-1268.
17. Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, Nugier F, Grange J, Malley S, Hamedi SF, and Vila J: Pilot clinical trial of the combination of hydroxyurea and didanosine. Antiviral Res 1996;29:111-113.
18. Montaner JS, Zala C, Conway B, Raboud J, Patenaude P, Rae S, O'Shaughnessy MV, and Schechter MT: A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997;175: 801-806.
19. Rabin RL, Roederer M, Maldonado Y, Petru A, and Herzenberg LA: Altered representation of naive and memory CD8 T cell subsets in HIV-infected children. J Clin Invest 1995;95:2054-2060.
20. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA, and Herzenberg LA: CD8 naive T cell counts decrease progressively in HIV-infected adults. J Clin Invest 1995;95:2061-2066.
21. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, and Detels R: Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: Results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1993;6: 904-912.
22. Mocroft A, Bofill M, Lipman M, Medina E, Borthwick N, Timms A, Batista L, Winter M, Sabin CA, Johnson M, Lee CA, Phillips A, and Janossy G: CDS+, CD38+ lymphocyte percent: A useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:158-162.
23. Borthwick NJ, et al.: Lymphocyte activation in HIV-1 infection. II. Functional defects of CD28-T cells. AIDS 1994;8:431-441.
24. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P, and Leibowitch J: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-116.
25. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, and Walker BD: Vigorous HTV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-1450.
26. Schwartz D, Sharma U, Busch M, Weinhold K, Matthews T, Lieberman J, Birx D, Farzedagen H, Margolick J, Quinn T, et al.: Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res Hum Retroviruses 1994;10:1703-1711.
27. Plana M, Garcia F, Gallart T, Miro JM, and Gatell JM: Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active antiretroviral treatment in early HIV-1 disease. Immunology Study Group of Spanish EARTH-1 Study. Lancet 1998;352:1194-1195.
28. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC, and Picker LJ: HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nature Med 1999;5:518-525.
29. Levy JA: Caution: Should we be treating HIV infection early? Lancet 1998;352:982-983.
30. Palmer S, Shafer R, and Merigan TC: Both nucleoside and nucleotide analogues are potentiated by hydroxyurea against drug-susceptible and drug-resistant HIV isolates. In: 2nd International Workshop on HIV Drug Resistance and Treatment Strategies 1998 Lake Maggiore, Italy, Abstract No. 3.
31. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, Walker B, and Lori F: Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999;340: 1683-1684.